Skip to main content
EJNMMI Research

Table 3 Mean serum creatinine at baseline, week 16 and corresponding differences with confidence intervals

From: Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [177Lu]Lu-DOTA-TATE in Lewis rats

Creatinine (mg/dl)

Baseline

Week 16

Difference (%)

Placebo

0.44 ± 0.05

0.45 ± 0.05

4 ± 13

Everolimus

0.44 ± 0.04

0.42 ± 0.04

− 4 ± 10

Placebo + [177Lu]Lu-DOTA-TATE

0.45 ± 0.05

0.58 ± 0.16

26 ± 25

Everolimus + [177Lu]Lu-DOTA-TATE

0.48 ± 0.04

0.46 ± 0.05

− 1 ± 16

Back to article page